Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Children's Oncology Group
mi
from
Arcadia, CA
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Children's Oncology Group
mi
from
Arcadia, CA
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Children's Memorial Hospital
mi
from
Chicago, IL
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Indiana University Medical Center
mi
from
Indianapolis, IN
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Johns Hopkins University
mi
from
Baltimore, MD
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE)
Status: Enrolling
Updated:  4/1/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE)
Status: Enrolling
Updated: 4/1/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Dallas, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Sedona, AZ
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Sedona, AZ
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Tucson, AZ
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Burbank, CA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Rancho Cucamonga, CA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Rancho Cucamonga, CA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Denver, CO
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Ocala, FL
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Woodbury, MN
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Woodbury, MN
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Columbia, MO
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Las Vegas, NV
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Nashville, TN
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Amarillo, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Austin, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Denton, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Denton, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
McAllen, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Tyler, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Spokane, WA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Yakima, WA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Yakima, WA
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Birmingham, AL
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Fayetteville, AR
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Washington,
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Honolulu, HI
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Charleston, SC
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/4/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/4/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/4/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/4/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Columbia University Medical Center
mi
from
New York, NY
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Bon Secours St. Francis Hospital
mi
from
Greenville, SC
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Bon Secours St. Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
The Mayo Clinic
mi
from
Rochester, MN
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/5/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/5/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials